이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Terumo 관리

관리 기준 확인 1/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

Hikaru Samejima

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	n/a
경영진 평균 재임 기간	less than a year
이사회 평균 재임 기간	3.1yrs

최근 관리 업데이트

Recent updates

CEO

Hikaru Samejima (60 yo)

less than a year

테뉴어

Mr. Hikaru Samejima served as Director of Terumo Corporation since February 7, 2024 until June 26, 2024 and serves as its Representative Director since June 26, 2024. He serves as President and CEO of Teru...

리더십 팀

이름	위치	테뉴어	보상	소유권
Hikaru Samejima	Representative Director	less than a year	데이터 없음	데이터 없음
Jin Hagimoto	CFO, CIO	less than a year	데이터 없음	데이터 없음
Shinji Omori	CTO, GM of DX Promotion Dept. R&D Division and Executive Officer	less than a year	데이터 없음	데이터 없음
Miho Mizuguchi	Executive Officer	8.3yrs	데이터 없음	데이터 없음
Tomoko Adachi	Chief Human Resources Officer & Group Executive Officer	1.5yrs	데이터 없음	데이터 없음
James Rushworth	Group Executive Officer & Chief Commercial Officer	1.5yrs	데이터 없음	데이터 없음
Kazunori Hirose	Director & Group Managing Executive Officer	no data	데이터 없음	0.0018% ¥ 446.8k
Itaru Sakaguchi	Group Managing Executive Officer	less than a year	데이터 없음	데이터 없음
Toshihiko Osada	Senior Managing Executive Officer & Director	no data	데이터 없음	데이터 없음
Fumihisa Hirose	Group Managing Executive Officer	less than a year	데이터 없음	데이터 없음
Norimasa Kunimoto	Director & Group Managing Executive Officer	1.3yrs	데이터 없음	0.0021% ¥ 520.9k
Antoinette Gawin	Group Senior Managing Executive Officer	less than a year	데이터 없음	데이터 없음

0.5yrs

평균 재임 기간

60yo

평균 연령

경험이 풍부한 관리: TRUM.Y 의 관리팀은 경험 (평균 재직 기간 0.4 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Hikaru Samejima	Representative Director	less than a year	데이터 없음	데이터 없음
Kazunori Hirose	Director & Group Managing Executive Officer	2.5yrs	데이터 없음	0.0018% ¥ 446.8k
Toshihiko Osada	Senior Managing Executive Officer & Director	less than a year	데이터 없음	데이터 없음
Norimasa Kunimoto	Director & Group Managing Executive Officer	1.1yrs	데이터 없음	0.0021% ¥ 520.9k
Soichiro Uno	Independent Outside Director	5.1yrs	데이터 없음	데이터 없음
Hidenori Nishi	Independent Outside Director	4.1yrs	데이터 없음	0.00022% ¥ 54.3k
Takanori Shibazaki	Director	3.1yrs	데이터 없음	0.0023% ¥ 565.3k
Toshiaki Takagi	Chairman of the Board & Group Managing Executive Officer	14.1yrs	JP¥131.00m	데이터 없음
Koichi Sakaguchi	Substitute Director	2.1yrs	데이터 없음	데이터 없음
Masaichi Nakamura	Independent Outside Director	5.1yrs	데이터 없음	0.00027% ¥ 66.7k
Keiya Ozawa	Independent Outside Director	3.1yrs	데이터 없음	0.000070% ¥ 17.3k
Takanori Shibasaki	Independent Outside Director	no data	데이터 없음	데이터 없음

3.1yrs

평균 재임 기간

64.5yo

평균 연령

경험이 풍부한 이사회: TRUM.Y 의 이사회는 경험(평균 재직 기간 4.5 년)으로 간주됩니다.

Terumo 관리

관리 기준 확인 1/4

주요 정보

최근 관리 업데이트

Shinjiro Sato to Leave as CEO of Terumo Corporation on April 1, 2024

Terumo Corporation, Annual General Meeting, Jun 27, 2023

Terumo Corporation, Annual General Meeting, Jun 22, 2022

Recent updates

Terumo Corporation to Report Q1, 2025 Results on Aug 08, 2024

Terumo Cardiovascular Announces 510(K) Clearance for the CDI Oneview™? Monitoring System

Terumo Corporation to Report Fiscal Year 2024 Results on May 14, 2024

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2024

Shinjiro Sato to Leave as CEO of Terumo Corporation on April 1, 2024

Terumo Corporation to Report Q3, 2024 Results on Feb 07, 2024

Terumo Corporation to Report Q2, 2024 Results on Nov 14, 2023

Terumo Corporation (TSE:4543) announces an Equity Buyback for 5,000,000 shares, representing 0.67% for ¥20,000 million.

Terumo Corporation to Report Q1, 2024 Results on Aug 09, 2023

Terumo Corporation Announces Fiscal Year-End Dividend for the Fiscal Year Ended March 31, 2023, Payable on June 28, 2023; Provides Second Quarter-End Dividend Guidance for the Fiscal Year Ending March 31, 2024 and Provides Year-End Dividend Guidance for the Fiscal Year Ending March 31, 2024

Terumo Corporation, Annual General Meeting, Jun 27, 2023

Terumo Corporation Provides Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2023

Terumo Corporation Announces Dividend for the Second Quarter End of Fiscal Year 2023, Commences Dividend Payments on December 5, 2022; Provides Dividend Guidance for the Fiscal Year Ending March 31, 2023

Terumo Corporation to Report Q3, 2023 Results on Nov 10, 2023

Terumo Corporation to Report Q2, 2023 Results on Nov 10, 2022

Mitsui DM Sugar Holdings Co.,Ltd. (TSE:2109) agreed to acquire Enteral formula business of Terumo Corporation from Terumo Corporation (TSE:4543).

NUTRI Co.,Ltd. entered into an agreement to acquire Nutritional food and related product assets of Terumo Corporation.

Terumo Corporation Provides Dividend Guidance for the Second Quarter of Year Ending March 31, 2023

Terumo Announces Change in Indication for Dexcom G6 CGM System in Japan

Terumo Corporation (TSE:4543) announces an Equity Buyback for 15,000,000 shares, representing 1.98% for ¥50,000 million.

Terumo Corporation to Report Fiscal Year 2022 Results on May 12, 2022

Terumo Corporation, Annual General Meeting, Jun 22, 2022

Terumo Corporation Revises Consolidated Earnings Guidance for the Fiscal Year Ending March 31, 2022

Terumo Corporation Provides Dividend Guidance for the Year Ending March 2022

Terumo Corporation (TSE:4543) signed definitive agreement to acquire All Assets from Health Outcomes Sciences, Inc.

Terumo Corporation Announces Clinical Study in Japan for Product Using Terumo's Automated Injection Device Developed in Collaboration with Kyowa Kirin Co., Ltd

Terumo Corporation Revises Earnings Guidance for the Fourth Quarter of Fiscal 2021

IceCure Medical Ltd Inks Expanded Distribution Agreement with Terumo Corporation for Thailand

Terumo Corporation to Report Q3, 2021 Results on Feb 04, 2021

Diabeloop SA. and Terumo Corporation Enter into Joint Development Agreement with Exclusive Distribution Right for Dblg1 Automated Insulin Delivery Solution in Japanese Market

IceCure Medical Ltd Expands Strategic Collaboration with Terumo Corporation, New Commercial Distribution Agreement Potentially Valued at over $7.0 Million

Terumo Corporation to Report Q2, 2021 Results on Nov 05, 2020

Terumo Corporation (TSE:4543) acquired ReThink Medical, Inc.

Terumo Corporation (TSE:4543) acquired remaining 80.1% stake in Quirem Medical B.V. for $45 million.

Terumo Corporation to Report Q1, 2021 Results on Aug 06, 2020

CEO

테뉴어

리더십 팀

평균 재임 기간

평균 연령

이사회 구성원

평균 재임 기간

평균 연령